Celebrating the draft FDA Bayesian guidance document with our perspective in @jama.com. Honored to co-author w/Jack Lee (MD Anderson), Lisa LaVange (past director of Office of Biostatistics FDA CDER&president of ASA),& my Bayesian inspiration Sir David Spiegelhalter jamanetwork.com/journals/jam...

📣 WHO invites feedback on the draft Guidance on Evidence Generation for TB Preventive Treatment (GEG-TPT) — open for public comment until 1 August 2025. Help shape future @WHO guidelines on #TB prevention. WHO Newsflash here: buff.ly/zaIVweX

WHO launches Public call for individual participant data on on BPaL, BPaLM, BPaLC and BDLC for the treatment of drug-resistant tuberculosis buff.ly/r1SqM8m

NEW PRE-PRINT (currently going through peer review) In this secondary analysis of the RIFASHORT trial we classified TB disease severity at baseline and show that for the majority of people 4-months of rifampicin-based treatment, without the use of a quinolone, was non-inferior to the 6-month SOC.

🌍 WHO kicks off work on the Guidance on Evidence Generation (GEG) for new #TB diagnostics! A clear playbook to help innovators & researchers produce the robust data WHO needs for rapid policy decisions. 🚀 #GlobalHealth #EndTB

If you are at a loose end next Tuesday, come hear me and @danieljgrint.bsky.social talk about endpoints in TB trials Hybrid event, in London and online Most of the same ideas available in written form here www.thelancet.com/journals/lan... #IDSky #TBSky @sgschumacher.bsky.social

JUST PUBLISHED: Results from the BEAT Tuberculosis trial of the 6-month BDLLxC regimen, which supported recently released updated #TB treatment guidelines buff.ly/FX9WdNR buff.ly/8w1xt4l

#Tuberculosis prevention and care relies heavily on international donor funding in many settings. In our latest preprint, we examine the potential impact of reductions in international donor funding for #TB - by the US and by other major donor countries. 1/8 www.medrxiv.org/content/10.1...

Just out! journals.plos.org/globalpublic... Clinical trial costs transparency as a tool to facilitate equitable access. A call to action! Please spread the word @msf.ca @madhupai.bsky.social @johngreensbluesky.bsky.social @catherineberry.bsky.social @sgschumacher.bsky.social @cdmitpih.bsky.social

GOOD NEWS: 25% price reduction for pretomanid - price of a BPaLM treatment course is now $310. The vast majority of DR-TB patients can benefit from this shorter, more effective regimen now. And it is cost-saving to health systems. Countries should transition away from other options rapidly.

WHO launches an update on the consolidated guidelines to diagnose #tuberculosis createsend.com/t/d-CCE83795...

JUST RELEASED: updated WHO TB treatment guidelines, including a recommendation for one new 6m and 3 new 9m regimens for DR-TB: createsend.com/t/d-0CC16B59...

Did you miss @tb-lshtm.bsky.social & @ucltb.bsky.social Symposium? Or would you like to watch again? Good news: the full recording is now available! tinyurl.com/bdh8fymx @sedonasweeney.bsky.social @kchorton.bsky.social @reinhouben.bsky.social

It was a great pleasure to attend the second WHO Global Clinical Trials Forum -- so much expertise gathered in a single room. www.linkedin.com/feed/update/...

Please someone tell me that this is fake news

Severe resource shortages are threatening the global response to end #tuberculosis (TB). A quarter of the world’s population could be infected with TB and not even know it. Is there a cure? What is the treatment? How do we diagnose TB? Listen in to Dr Tereza Kasaeva on Science in 5. bit.ly/4kRdJXE

Last year we released WHO Guidance on evidence generation (GEG) on new regimens for #TB treatment — a first-of-its-kind document that provides advise on how evidence should be generated to optimally inform WHO guideline development: bsky.app/profile/sgsc... www.who.int/publications...

Great to see more data coming out from programmatic implementation of BPaLM (Belarus, Uzbekistan, Pakistan): ~800 patients & >90% success rate! pubmed.ncbi.nlm.nih.gov/39964841/ pubmed.ncbi.nlm.nih.gov/39544887/ No FU post-Rx completion since based on routine data - but still good to see this

It was a great pleasure to talk about our work -- here an overview of the 21 key messages from the guidance and the link to the full document: iris.who.int/bitstream/ha...

Amidst all the bad news these days, I much enjoyed listening to this interview with Dr Rajiv Bahl, DG of @ICMRDELHI. Wonderful and inspiring to hear his vision for ICMR. The positive impact I expect it will have on the future of Global Health gives me hope. buff.ly/NUoUhPy

SMART4TB "axed" amidst dismantling of USAID

Just out: summary of WHO consultation on asymptomatic TB (aka subclinical TB) createsend.com/t/d-DDBC4043...

Challenge to the #TB community.... what are the RCT's we really need to push things forward in TB? @who.int is putting a call out as part of their Global Clinical Trials Forum. www.thelancet.com/journals/lan... @catherineberry.bsky.social @madhupai.bsky.social @sgschumacher.bsky.social

Vasee Moorthy and Jeremy Farrar call for Identifying key randomised clinical trials that could transform clinical care and public health in @thelancet.bsky.social www.thelancet.com/journals/lan...

With its anti-science and anti-public health policies, the US is now at risk for outbreaks of tuberculosis As @johngreensbluesky.bsky.social put it, "TB is both a form and expression of injustice" www.thelancet.com/journals/lan...

Proud to see the endTB trial, work of a huge team, led by @partnersinhealth.bsky.social, @msf.org, IRD & supported by @unitaid.bsky.social, published in @nejm.org today. Safe, effective, shortened treatments for drug-resistant TB can be available to all. #TBSky #ForeignAid tinyurl.com/NEJM-endTB

WHO takes forward the establishment of a country-led, streamlined platform for clinical trials in #TB treatment createsend.com/t/d-B1426282...

Please share widely. @madhupai.bsky.social @fvlscience.bsky.social @dopapus.bsky.social @sgschumacher.bsky.social

Exciting to see TB Champ and V-quin, FQ preventative therapy for MDR-TB in print. Congratulations to @jaseddon.bsky.social, Anneke Hesseling, Greg Fox and co-authors. @actnet.bsky.social @absteward.bsky.social @citc-tb.bsky.social @sgschumacher.bsky.social @kncvtbplus.bsky.social @tbfighters.org

Today WHO released Guidance on evidence generation (GEG) on new regimens for #TB treatment — a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development.

WHO launches new clinical trials guidance – What do I need to know?

LIFT-TB results on operational research with BPaL among 574 patients in Indonesia, Kyrgyzstan, Myanmar, Philippines, Ukraine, Uzbekistan, Vietnam suggest 91% efficacy

READ THIS: Clinical trials versus the real world in tuberculosis control Editorial from @thelancet.bsky.social Infectious Diseases. Could not agree more with many of the challenges outlined here in relation to clinical trials. https://buff.ly/4i8LJ0d

In the coming weeks we will release 'Guidance on evidence generation (GEG) on new regimens for tuberculosis treatment' -- a first-of-its-kind WHO document.

🚨New Publication🚨 led by @biancasossen.bsky.social In a 7 country study, we found that urine Xpert Ultra was as sensitive & more specific than AlereLAM for #TB diagnosis in people with #HIV Also predicts mortality and allows detection of Rif resistance. authors.elsevier.com/sd/article/S... 🧪🛟

Interim results from endTB-Q: 6-9m BDCL (86%) vs 18m standard of care regimen (88%) favorable outcomes. A lot more to unpack... https://buff.ly/4fCqO3z https://buff.ly/3YZTJZT Protocol here: https://buff.ly/40BhHMo

New guidance document on clinical trials just published by WHO. Strongly encourage anyone working on clinical trials to read this document https://buff.ly/3XWHRap

"In 2023, Tuberculosis (TB) probably returned to being the world’s leading cause of death from a single infectious agent, following 3 years in which it was replaced by coronavirus disease (COVID-19), and caused almost twice as many deaths as HIV/AIDS." https://buff.ly/3C3Hsuw

Otsuka announcing their plans for a Phase 3 trial of their novel #TB drug Quabodepistat (sorry for the poor resolution). Good to see one of the novel drugs move ahead to a registrational trial!

Updated clinical pipeline by the Working Group for New Drugs - @newtbdrugs https://buff.ly/3Atygzg